Vaxart, Inc. To Present Phase I Data At IDWeek 2015 Demonstrating Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a privately held, clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that Vaxart Associate Director of Immunology Wendy Peters, Ph.D., will present Phase 1 data demonstrating the Vaxart H1N1 influenza tablet vaccine induces dose dependent T cell responses at the upcoming IDWeek 2015 in San Diego.

“An Adenovirus Based Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses”

Dr. Peters will report the data in her poster presentation, “An Adenovirus Based Influenza Tablet Vaccine Induces Dose Dependent T Cell Responses” on Friday, Oct. 9 from 12:30 to 2 p.m. Pacific Daylight Time in Poster Hall at the San Diego Convention Center.

About Vaxart

Vaxart is a privately held, clinical-stage company developing a range of tablet vaccines based on its proprietary oral recombinant vaccine platform. Vaxart’s vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer, and eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. Vaxart’s lead programs include tablet vaccines for seasonal influenza, norovirus and Respiratory Syncytial Virus (RSV). For more information, please visit www.vaxart.com.